Rystiggo (rozanolixizumab) has been given the green light by the FDA for both anti-AChR and anti-MuSK antibody-positive gMG based on the results of the MycarinG study, which showed that treatment ...

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

Among 12 abstracts shared, the company highlighted pivotal Phase 3 study findings and real-world data underscoring the treatment’s promise and the ongoing unmet needs in gMG care. Key findings ...

Brisbane, Queensland, Australia--(Newsfile Corp. - April 25, 2025) - Graphene Manufacturing Group Limited (TSXV: GMG) ("GMG" or the "Company") provides a quarterly update with respect to the Company's ...